NCT06995729View on ClinicalTrials.gov

A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 16, 2025

Primary Completion Date

August 12, 2027

Study Completion Date

August 12, 2027

Conditions
Acute Treatment of Migraine
Interventions
DRUG

Zavegepant

Zavegepant 5 mg or 10 mg (dose is weight-dependent)

Trial Locations (8)

20016

NOT_YET_RECRUITING

Velocity Clinical Research, Washington DC, Washington D.C.

28625

NOT_YET_RECRUITING

Accellacare - Piedmont, Statesville

NOT_YET_RECRUITING

Accellacare of Piedmont HealthCare, Statesville

31313

RECRUITING

Coastal Heritage Clinical Research, Hinesville

55402

NOT_YET_RECRUITING

Clinical Research Institute, Minneapolis

74136

NOT_YET_RECRUITING

Central States Research, Tulsa

84107

NOT_YET_RECRUITING

Wasatch Clinical Research, LLC, Salt Lake City

84117

NOT_YET_RECRUITING

Granger Medical Holladay - Holladay Clinic, Salt Lake City

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06995729 - A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine | Biotech Hunter | Biotech Hunter